" class="no-js "lang="en-US"> Sanofi - Medtech Alert
Thursday, June 20, 2024
Sanofi | Pharmtech Focus

Sanofi

About Sanofi

Sanofi

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care.

From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare.

More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.

Related Story

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

March 21 2023

Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) has approved Dupixent (dupilumab) […]

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

January 30 2023

Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) expanded the marketing authorization […]

Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

August 19 2022

Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced […]

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

August 8 2022

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes […]

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

July 6 2022

Skyhawk Therapeutics, Inc. today announced the signing of an exclusive worldwide collaboration agreement with Sanofi […]

Sanofi-GSK Next-generation COVID-19 Booster Delivers Strong Immune Response Against Variants of Concern, Including Omicron

June 14 2022

Sanofi today reports data from two trials, VAT02 Cohort 2 and COVIBOOST VAT013, conducted with […]

Sarclisa® (Isatuximab) Combination Provides Unprecedented Median Progression Free Survival in Patients With Relapsed Multiple Myeloma Receiving a Proteasome Inhibitor Therapy

May 16 2022

Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® (isatuximab) in combination with carfilzomib […]

Sanofi and Seagen Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-drug Conjugates

March 17 2022

Sanofi and Seagen Inc. (Nasdaq:SGEN) today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates […]

Sanofi Announces €300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment for Multiple Myeloma

March 16 2022

Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed […]

NovAliX Signs Partnership Agreement to Design and Screen Sanofi’s New DNA-Encoded Libraries

November 30 2021

NovAliX, a Contract Research Organization (CRO) specializing in drug research and development, today announces its […]

Sanofi Invests $180 Million Equity in Owkin ’s Artificial Intelligence and Federated Learning to Advance Oncology Pipeline

November 19 2021

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with […]

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer

October 8 2021

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement […]

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology Across Vaccines and Therapeutics Development

August 4 2021

As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop […]

New Soliqua ® Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin

June 29 2021

A new study of Soliqua (insulin glargine 100 Units/mL and lixisenatide, iGlarLixi) met its two […]

Libtayo ® (Cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers

May 25 2021

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted […]

Sanofi and GSK COVID-19 Vaccine Candidate Demonstrates Strong Immune Responses Across All Adult Age Groups in Phase 2 Trial

May 18 2021

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody […]

Sanofi Establishes Three-year Collaboration with Stanford Medicine to Accelerate Immunology Research

May 7 2021

Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, […]

Sanofi Acquires Tidal Therapeutics

April 12 2021

Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel […]